Objective     To investigate the clinical efficacy

safety and tolerability of 0.1% bromfenac sodium hydrate ophthalmic solution in myopia and astigmatism eyes after subbowman keratomileusis (SBK).      Methods      A randomized and controlled clinical study was employed. The patients undergoing SBK for high myopia and myopic astigmatism were enrolled in the study. The myopia degree was -6.00 D to -10.00 D

and the astigmatism degree was ≤ -4.00 D. The patients were randomly divided into the experiment group (bromfenac sodium

72 eyes) and the control group (loteprednol

72 eyes) with a random number table method. Both groups initially received tobramycindexamethasone 4 times a day for 3 d after SBK. Then the patients in the experiment group were given bromfenac sodium twice a day for 1 month

while the patients in the control group were given loteprednol twice a day for 1 month. Visual acuity

refraction

intraocular pressure (IOP) and corneal symptom were examined before SBK and in 1 d

1 week

1

3 and 6 months after SBK.     Results       There was no statistically significant difference in the visual acuity and refraction between the 2 groups postoperatively (P0.05). There was no statistically significant difference in the IOP between the 2 groups in 1 week after SBK (P0.05). The control group had higher IOP than the experiment group in 1

3 and 6 months after SBK (P0.05). All patients in the experiment group were no drug withdrawal. But 6 eyes in the control group were forced to guide drug withdrawal because of high IOP.   Conclusion         Bromfenac sodium has good safety

efficacy and tolerability to the patients undergoing SBK for correcting myopia and astigmatism

and can reduce the incidence of high IOP.